Table 3 Discontinuation rates of ibrutinib in published clinical trials
1st author | Study | Median duration of treatment in months (range) | Discontinuation rate (%) | Reason for dose discontinuation (%) | Dose reduction 1 year (%) | |||
|---|---|---|---|---|---|---|---|---|
Non-relapse disease | Relapsed disease | |||||||
Toxicity/AE | Death not secondary to CLL/AE | Patient preference/other | CLL progression | |||||
Byrd et al. [1] | RESONATE | 8.6 (0.2–16.1) | 13.8 | 29.6 | 29.6 | 7.4 | 33.3 | NR |
Byrd et al. [1] | RESONATE long-term FU | 41 (0.2–50.1) | 53.8 | 22 | 11.4 | 16.1 | 50.5 | 6 |
Burger et al. [3] | RESONATE-2 | 17.4 (0.7–24.7) | 12.5 | 64.7 | 17.6 | 5.9 | 11.8 | NR |
Barr et al. | RESONATE-2 long term FU | 28.5 (0.7–35.9) | 20 | 78.6 | 7.1 | 14.3 | 9 | |
O’Brien et al. [23] | RESONATE-17 | 11.5 (11.1–13.8) | 50 | 33 | 20 | 47 | 7 | |
Ahn et al. [6] | Ahn et al. | 4.8 years (4–6 years) | 43 | 13 | 11 | 22 | 54 | NR |
Byrd et al. [1] | NEJM 2013-PCYC 1102 | 20.9 (0.7–26.7) | 36 | 22.5 | 0 | 42 | 35.5 | NR |
O’Brien et al. [24] | Lancet 2014-PCYC 1102 phase 1b/2 | 22.1 (18.4–23.2) | 16 | 40 | NR | 40 | 20 | NR |
Byrd et al. [1] | PCYC 1103 | 25 (0.3–45) | 40 | 28 | NR | 30 | 42 | NR |
Coutre et al. [4] | PCYC 1103 | 30 (1–44) | 34 | 37 | 0 | 25 | 28.1 | NR |
O’Brien et al. | PCYC 1103 | 62 (1–75) | 66 | 31 | NR | 27.6 | 40 | NR |